breast-cancer-congress-2017-posters-abstracts

7 / 15

Page 61
conferenceseries .com
6th World Congress on
October 16-18, 2017 | San Francisco, USA
Breast Cancer & Therapy
Volume 2, Issue 5 (Suppl) Breast Can Curr Res, an open access journal Breast Cancer Congress 2017
October 16-18, 2017
The potential of circulating tumor cells (CTCs) in personalized management of breast cancer:Asystematic
review
Fatemeh Khatami, Hamid Reza Aghayan, Maryam Sanaei, Ramin Heshmat, Seyed Mohammad Tavangar and Bagher Larijani
Tehran University of Medical Sciences , Iran
C irculating tumor cells (CTCs) detection and characterization in the peripheral blood of breast cancer patients has proven practical
and predictive value in different studies. However, the clinical significance of CTCs enumeration and molecular characterization
in personalization of breast cancer diagnosis and treatment remains under the debate. A literature search in PubMed, Web of Science
and Scopus was performed from October 1990 to June 2016 for studies which evaluated CTCs and its association with clinical and
pathological characteristics and medical outcome in the field of breast cancer personalization for both diagnosis and treatment
categories. The treatment outcomes were progression-free survival (PFS) and overall survival (OS) or relapse in different patients.
Sixty nine studies met the inclusion criteria. The sample size varies from 1 to 2026. Median follow-up was 15 months (range 3-27).
Different molecular techniques have been applied for research but they mostly are based on CTCs enrichment and then detection
by using FDA-approved Cell SearchTM. By far the most studies define CTCs as cytokeratins (CK) positive and CD45 negative
cells. Despite the differences in methodology, thirty two studies for breast cancer diagnosis and prognosis were mainly focused on
CTCs isolation and enumeration. Thirty seven research were about CTCs count and exact molecular characterization. In the way
of precision treatment, detection of CTCs before initiation of first-line therapy or during therapy in patients with breast cancer is
highly valuable but in the way of precision medicine it should be supported with some molecular characteristics of CTCs like CTCs
phenotypic changes, gene expression analysis of CTCs and molecular characteristics of CTCs.
Breast Can Curr Res 2017, 2:5 (Suppl)
DOI: 10.4172/2572-4118-C1-012